Epicareer Might not Working Properly
Learn More
Back

Apellis Pharmaceuticals

About the Company

Apellis Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of complement-mediated diseases. The company's lead product candidate, pegcetacoplan, is a targeted C3 therapy designed to address the underlying cause of several debilitating diseases, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), and C3 glomerulopathy (C3G). Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts. The company has a global presence with operations in Europe and Asia, and has a team of over 300 employees dedicated to advancing the development of life-changing therapies for patients in need.

Industry Type

According to the GICS (Global Industry Classification Standard) version of March 2023, Apellis Pharmaceuticals’s industry classification falls within the following categories:
  • Sector: Health Care
  • Industry group: Pharmaceuticals, Biotechnology & Life Sciences
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
Videos and Photos

Company Address

100 Fifth Avenue Waltham, MA 02451 United States

Source : Google maps